Karyopharm Therapeutics Inc (FRA:25K)
€ 0.5734 -0.0194 (-3.27%) Market Cap: 84.88 Mil Enterprise Value: 143.15 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 64/100

Karyopharm Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 14, 2020 / 06:00PM GMT
Release Date Price: €15.4 (-4.35%)
Eric William Joseph
JP Morgan Chase & Co, Research Division - VP & Senior Analyst

Good morning. I'm Eric Joseph, one of the senior biotech analysts at JPMorgan. And our next presenting company is Karyopharm Pharmaceuticals -- or Karyopharm Therapeutics, rather. It's my pleasure to welcome CEO, Michael Kauffman, to tell us a little bit about the company. Just as a reminder, the Q&A breakout session will be held in the Sussex Room. With that, Michael?

Michael G. Kauffman
Karyopharm Therapeutics Inc. - Co-Founder, CEO & Director

Thanks, Eric, and welcome, everybody today. It's great to be here. It's been a heck of a year for us and dive right in. As you all know, I'll make forward-looking statements. Please do review this slide and all the information in it. Now you're done reviewing. .

Karyopharm's vision is to become a leading oncology company. We are the first company that has received approval for an oral Exportin 1 inhibitor, XPOVIO, and we have a few direct competitors in development. XPOVIO, U.S. accelerated approval occurred on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot